|
NR. 2/2007
|
|
|
|
|
|
|
|
|
Próba standaryzacji
leczenia zaawansowanych przypadków zespołu suchego oka na
podstawie szerokiego spektrum leczenia miejscowego i ogólnego,
ze szczególnym uwzględnieniem zastosowania doustnego preparatu
chlorowodorku pilokarpiny
The Trial of Severe Dry Eye
Treatment Standardization on the Basis of Wide Spectrum of
Topical and Systemic Therapy with Special Emphasis Placed on
Oral Pilocarpine Hydrochloride Administration
Anna Wójcik-Gryciuk
Katedra i Klinika Okulistyki II Wydziału Lekarskiego Akademii
Medycznej w Warszawie
Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik |
|
|
|
|
|
|
| Summary: |
Dry eye syndrome is an eye
disease caused by decreased tear production or increased
tear film evaporation. The common cause of severe dry
eye cases is Sjögren’s syndrome – chronic autoimmune
disorder characterized by infiltration of exocrine
glands, particularly the salivary and lacrimal glands by
lymphocytes and plasma cells. The classic signs of
Sjögren’s syndrome include xerostomia and xerophthalmia
related to diminished lacrimal and salivary gland
function. Sjögren’s syndrome exists in a primary and
secondary form.
The basic treatment of dry eye syndrome consists in
regular use of eye drops and gels without preservatives
which help to stabilize the tear film and provide
protection to cornea and conjuctiva.
The aim of this paper is to present the influence of
pilocarpine hydrochloride administered orally on
attenuation the severe dry eye symptoms. Pilocarpine is
a cholinergic parasympathomimetic agent exerting a broad
spectrum of pharmacologic effects with predominant
muscarinic action. Pilocarpine, in appropriate dosage,
can increase secretion by the exocrine glands.
The author also describes other methods of
pharmacological and surgical therapies which play role
in severe dry eye syndrome treatment. |
|
|
| Key words: |
oral pilocarpine
hydrochloride, Sjögren’s syndrome, tear film, dry eye
syndrome. |
|
|
|
|
|
|
|
|
